Valve Surgery



Delayed Coronary Occlusion After Transcatheter Aortic Valve Implantation: Implications for New Transcatheter Heart Valve Design and Patient Management

Transcatheter aortic valve implantation (TAVI) has undoubtedly revolutionised the treatment of severe aortic stenosis and has become the preferred treatment option for patients at increased surgical risk.1,2 Although outcomes have improved and complications reduced over time, certain potentially catastrophic complications remain.3,4 Coronary obstruction has long been a feared complication and is classically recognised to occur in the acute setting just after valve deployment.

Transseptal Transcatheter Mitral Valve Replacement for Post-Surgical Mitral Failures

Approximately 1.8 % of the US population has mitral valve disease,1 and an estimated 106,000 surgeries per year are for the treatment of valvular heart disease.2 A total of 210,529 mitral surgeries were performed from 2000 to 2007, averaging approximately 30,000 mitral valve surgeries yearly in the US, accounting for both combined and isolated mitral procedures, with approximately 60 % of surgeries using a bioprosthetic valve.3 Unfortuna

Coronary Revascularisation in Transcatheter Aortic Valve Implantation Candidates: Why, Who, When?

The prevalence of concomitant coronary artery disease (CAD) in patients with severe aortic stenosis (AS) varies widely among different reports. This depends primarily on the definition used to assess CAD as well as study design and patient selection, therefore making a uniform estimate difficult.

Diagnosis and Outcomes of Transcatheter Aortic Valve Implantation in Bicuspid Aortic Valve Stenosis

Bicuspid aortic valve is the most common congenital cardiac malformation, affecting 1.3 % of the population, and responsible for a significant proportion of aortic valve replacement in adults.1-3 Clinical presentation varies from severe valve disease in infancy to asymptomatic valve in old age, but symptoms typically develop in adulthood.